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ABSTRACT 
Objective: A selective, sensitive and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay has been developed for the 
determination of celecoxib (CXB) in negative ionization mode.  
Methods: Celecoxib and celecoxib-D7 (CXB-D7) as internal standard (IS) were extracted from 300 µl human plasma by solid-phase extraction using 
strata-X SPE cartridges. Chromatographic separation was achieved on ACE C8-300 (50 × 4.0 mm, 3.0 μm) column using methanol-1.0 mmol 
ammonium acetate solution in 80:20 (v/v) ratio. The protonated precursor to product ion transitions studied for CXB and CXB-D7 were m/z 380.0 
→ 315.9 and 387.0 → 323.0, respectively.  
Results: The limit of detection (LOD) and lower limit of quantitation of the method were 2.50 and 10.0 ng/ml respectively with a linear dynamic 
range of 10.0-4000 ng/ml for CXB. The intra-batch and inter-batch precision (% CV) and mean relative recovery across quality control levels is<7.2 
% and 85.5 % respectively. Matrix effect in human plasma, expressed as IS-normalized matrix factor ranged from 0.99-1.03.  
Conclusion: The method was successfully applied in healthy subjects using a single dose of 400 mg celecoxib capsules under fasting and fed 
conditions. The reproducibility in the measurement of study data is demonstrated by incurred sample reanalysis. 
Keywords: Celecoxib; LC-MS/MS; Solid-phase extraction; Human plasma; Bioequivalence study; Incurred sample reanalysis  




Celecoxib (CXB) is the first cyclooxygenase 2-selective inhibitor 
introduced into clinical practice. It is approved worldwide for the 
relief of the signs and symptoms of osteoarthritis, rheumatoid 
arthritis and ankylosing spondylitis. It is used in the management 
and treatment of primary dysmenorrhoea and for acute pain in 
adults [1]. After oral administration of 200 mg of celecoxib to 
healthy volunteers the maximum plasma concentration (Cmax, 450-
800 ng/ml) is reached in 1.5-3 h. The low solubility of the drug 
appears to prolong the absorption process making terminal half-life 
(t1/2) determinations more variable. Under fasted conditions, t1/2
Various methods have been reported for the determination of CXB in 
biological fluids. This includes liquid chromatography (LC) with 
spectrophotometric detection [3-7], liquid chromatography-mass 
spectrometry (LC-MS) [8], ultra performance LC-inductively coupled 
plasma mass spectrometry (UPLC-ICPMS) [9] and LC coupled with 
tandem mass spectrometry (LC-MS/MS) [10-12]. Several of these 
methods involve tedious liquid-liquid extraction (LLE) for sample 
preparation [4, 5, 8, 9, 11]. In two previous methods [6, 7], protein 
precipitation (PP) was employed, but the spectrophotometric 
detection at 254 nm was less selective and therefore necessitated 
chromatographic separation of CXB and internal standard from 
endogenous interferences. This resulted in longer chromatographic 
analysis times (≥6 min). Except one report [12], all other  methods 
have long analysis time and required extensive sample preparation. 
 is 
approximately 9-11 h. Due to the low aqueous solubility of CXB, 
absolute bioavailability studies have not been conducted [1, 2]. 
Thus, the aim of this study was to simplify sample preparation step 
using solid phase extraction (SPE) and simultaneously to shorten the 
chromatographic run time with a more selective LC-MS/MS 
procedure. Further, to improve the precision and accuracy of the 
method isotopically labeled CXB was used compared to general 
internal standards employed in previously studies [8, 11, 12]. These 
improvements enabled development of a rapid, selective and 
sensitive LC-MS/MS method for determination of CXB in human 
plasma. The method was successfully applied to a pharmacokinetic 
study under fed and fasting states. 
MATERIALS AND METHODS 
Chemicals and materials  
Reference standards of CXB (99.53 %) and celecoxib-D7 (IS, 98.42 
%) were purchased from Clearsynth Labs (P) Ltd. (Mumbai, India). 
HPLC grade methanol, analytical grade formic acid and ammonium 
acetate were obtained from SD Fine Chemicals Ltd. (Mumbai, India). 
Deionized water for LC-MS/MS was prepared using Milli Q water 
purification system from Millipore (Bangalore, India). Samples were 
centrifuged on Eppendorf 5810 centrifuge machine (Hamburg, 
Germany). Phenomenex Strata-X® (1 cc, 30 mg) extraction cartridges 
were procured from Phenomenex (Hyderabad, India). Control 
buffered (K2
LC-MS/MS instrumentation and conditions 
-EDTA) human plasma was obtained from Clinical 
Department, Cliantha Research India Limited (Ahmedabad, India) 
and was stored at–20 °C until use.  
The liquid chromatography system from Shimadzu (Kyoto, Japan) 
consisted of a LC-10ADvp pump, an autosampler (SIL-HTc) and an 
on-line degasser (DGU-14A). Chromatographic analysis was 
performed on ACE C8-300 (50 × 4.0 mm, 3.0 μm) column from 
Chromatopak Analytical Instrumentation Pvt. Ltd. (Mumbai, India). 
The mobile phase consisting of methanol-1.0 mmol ammonium 
acetate in 80:20 (v/v) ratio, was delivered at a flow rate of 0.5 
ml/min. The auto sampler temperature was maintained at 4 °C and 
the injection volume was 2.0 μl. The total LC run time was 2.5 min. 
Ionization and detection of CXB and IS was performed on a triple 
quadrupole mass spectrometer, API-4000 equipped with Turbo Ion 
spray®, from MDS SCIEX (Toronto, Canada) and operated in the 
negative ionization mode. Quantitation was done using multiple 
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reaction monitoring (MRM) mode to monitor protonated precursor 
→ product ion transition of m/z 380.0 → 315.9 for CXB and 387.0 → 
323.0 for IS. All the parameters of LC and MS were controlled by 
Analyst software version 1.6.2. 
The source dependant mass parameters maintained for CXB and IS 
were Gas 1(nebulizer gas): 55 psi, Gas 2(heater gas): 60 psi, ion 
spray voltage (ISV):-4500 V, turbo heater temperature: 500 °C, 
collision activation dissociation (CAD): 8 psi, curtain gas (CUR): 25 
psi. The compound dependent parameters like declustering 
potential (DP), collision energy (CE), entrance potential (EP) and cell 
exit potential (CXP) were optimized at-120,-39,-10 and-10 V for CXB 
and-120,-35,-10 and-20 V for IS respectively. Quadrupole 1 and 
quadrupole 3 were maintained at unit resolution and the dwell time 
was set at 500 ms. 
Preparation of standard stock and plasma samples 
Separate standard stock solutions (500 µg/ml) were prepared by 
dissolving requisite amount of CXB and CXB-D7 in methanol. The 
CXB solution was further diluted appropriately to get an 
intermediate concentration of 80.0 µg/ml. The working solutions of 
CXB required for spiking plasma calibration and quality control 
samples were prepared using the standard and intermediate stock 
solutions in methanol: water (90:10, v/v). IS working solution of 
1500 ng/ml was prepared using the stock solutions in deionized 
water. The calibration standards (CSs) and quality control (QC) 
samples (LLOQ QC, lower limit of quantitation quality control; LQC, 
low quality control; MQC-1 and MQC-2, medium quality control; HQC, 
high quality control; ULOQ QC, upper limit of quantitation quality 
control) were prepared by spiking blank plasma with respective 
working solutions. CSs were made at 10.0, 20.0, 50.0, 100, 200, 400, 
800, 1600, 3200 and 4000 ng/ml. QCs were prepared at 10.0 ng/ml 
(LLOQ), 30.0 ng/ml (LQC), 300 ng/ml (MQC-2), 1200 ng/ml (MQC-1), 
3000 ng/ml (HQC) and 4000 ng/ml (ULOQ) for CXB. Standard stock 
and working solutions used for spiking were stored at 2-8 °C, while 
CSs and QC samples in plasma were kept at-20 °C until use. 
Protocol for sample preparation  
Prior to analysis, spiked plasma samples were thawed and allowed to 
equilibrate at room temperature. The samples were adequately 
vortexed using a vortexer before pipetting. Aliquots of 300 µl plasma 
solutions containing 15 µl of working solution of CXB and 285 µl blank 
plasma were transferred into ria vials. Further, 15 µl of methanol: 
deionized water (90:10, v/v), 100 µl working solution of IS (1500 
ng/ml) was added and vortexed to mix. To the same vials, 100 µl of 2 
% formic acid solution was added and vortexed again. Prior to loading 
plasma samples, SPE cartridges were pre-washed with 1.0 ml of 
methanol, followed by 1.0 ml of deionized water and centrifuged for 
1.0 min at 1811 × g. Plasma samples were then applied to these 
conditioned cartridges and after centrifugation for 2.0 min at 1811 × g, 
washing was done with 1.0 ml of deionized water, followed by 
centrifugation for 1.0 min at 1811 × g. Elution was carried out with 2.0 
× 250 µl of methanol-1.0 mmol ammonium acetate (80:20, v/v), 
followed by centrifugation for 1.0 min at 1811 × g after each step and 
2.0 µl was used for injection in LC-MS/MS, in partial loop mode.  
Methodology for validation 
Method validation for CXB in human plasma was done following the 
USFDA guidelines [13] and the procedures followed were similar to 
reported methods [14, 15]. The method was validated for selectivity, 
interference check, carryover, linearity, precision and accuracy, 
reinjection reproducibility, recovery, ion suppression/enhancement, 
matrix effect, stability, dilution integrity and ruggedness.  
Bioequivalence study design and incurred sample reanalysis (ISR) 
The design of the study comprised of “An open label, randomized, 
two period, two treatment, two sequence, crossover, balanced, 
single dose, evaluation of relative oral bioavailability of test (400 mg 
celecoxib capsules from an Indian company) and reference 
formulations (CELEBREX®, 400 mg celecoxib capsules from G. D. 
Searle LLC, Pfizer Inc, NY, NY 10017 USA) in 50 healthy Indian male 
subjects under fasting and 42 healthy Indian male subjects under fed 
conditions. The study was carried out at Bio-Analytical Laboratory, 
BA Research India Ltd., Ahmedabad, India. All the subjects were 
informed of the aim and risk involved in the study and a written 
consent were obtained. The inclusion criteria for volunteer selection 
was based on the age (18-45 y), body mass index (18.5-24.9 
kg/height2), general physical examination, electrocardiogram and 
laboratory tests like haematology, blood chemistry, urine 
examination and immunological tests. The exclusion criteria 
included allergic responses to CXB, volunteers with history of 
alcoholism, smokers and having a disease which may compromise 
the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, 
respiratory, central nervous system, diabetes, psychosis or any other 
body system. The work was approved and subject to review by 
Institutional Ethics Committee, an independent body comprising of 
eight members that included a lawyer, medical doctors, social 
workers, pharmacologists and academicians. The procedures 
followed while dealing with human subjects were based on 
International Conference on Harmonization, E6 Good Clinical 
Practice guidelines [16]. The subjects were fasted 10 h before 
administration of the drug formulation for fasted study. For fed 
study, the subjects were fasted 10 h prior to serving standardized 
high-calorie and high-fat breakfast. Subjects remained seated in an 
upright position on bed for initial 4.0 h post-dose and only necessary 
movement was allowed during this period for both the studies. 
Water intake was restricted 1.0 h before and after dosing. Blood 
samples were collected in vacutainers containing K2
The pharmacokinetic parameters were estimated by non-
compartmental model using WinNonlin software version 5.2.1 
(Certara, Princeton, NJ 08540, USA). The C
EDTA at 0.0 
(pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 10, 12, 
24, 36, 48 and 72 h for fasting study and at 0.0 (pre-dose), 1.0, 2.0, 
3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, 24, 36, 48 and 72 h for fed 
study after oral administration of the drug. Blood samples were 
centrifuged at 1811 g at 4 °C for 15 min; the plasma obtained was 
separated and stored at-20 °C until use.  
max values and the time to 
reach maximum plasma concentration (Tmax) were estimated 
directly from the observed plasma concentration vs. time data. The 
area under the plasma concentration–time curve from time 0 to 72 h 
(AUC0-72h) was calculated using the linear trapezoidal rule. The 
AUC0-inf  was calculated as: AUC0-inf  = AUC0-24h+C t/Kel, where C t  is the 
last plasma concentration measured and Kel  is the elimination rate 
constant; Kel  was determined using linear regression analysis of the 
logarithm linear part of the plasma concentration–time curve. The 
t1/2 of CXB was calculated as: t1/2 = ln2/Kel . To determine whether 
the test and reference formulations were pharmacokinetically 
equivalent, Cmax, AUC0-72h, and AUC0-inf  and their ratios 
(test/reference) using log transformed data were assessed; their 
means and 90 % CIs were analyzed by using SAS®
An incurred sample re-analysis (ISR) was also conducted by 
computerized random selection of 316 subject samples near C
 software version 
9.1 (SAS Institute Inc., Cary, NC, USA). The drugs were considered 
pharmacokinetically equivalent if the difference between the 
compared parameters was statistically non-significant (P ≥ 0.05) 
and the 90 % confidence intervals (CI) for these parameters were 
within 80-125 %.  
max
RESULTS AND DISCUSSION 
 
and the elimination phase for this study as reported previously [17]. 
The results obtained were compared with the data obtained earlier 
for the same sample using the same procedure. As per the 
acceptance criterion at least two-thirds of the original and repeat 
results should be within 20 % of each other.  
Method development 
The objective of the present work was to develop and validate a 
simple, rugged, selective and sensitive method for CXB in human 
plasma by LC-MS/MS for routine sample analysis. Also, the 
sensitivity of the method should be adequate to monitor at least five 
half lives of CXB concentration with good accuracy and precision for 
subject sample analysis. During method development, electro spray 
ionization of CXB and CXB-D7 (IS) was conducted in negative 
ionization mode as both are basic in nature due to presence of 
tertiary and secondary amine groups, using 10.0 ng/ml tuning 
solution. The analyte and IS gave predominant singly charged 
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ions at m/z of 380.0 and 387.0 for 
CXB and IS, respectively in Q1 full scan spectra as reported 
previously [10]. Further, fragmentation was initiated using sufficient 
nitrogen for CAD and by applying 25.0 psi curtain gas to break the 
precursor ions. The most abundant and consistent ion found in the 
product ions in Q3 mass spectra of CXB and IS were at m/z 315.9 
and 323.0, respectively. These ions were formed from the 
deprotonated parent ion by removal of sulfur dioxide (fig. 1a and 
1b). To attain an ideal Taylor cone for better spectral response, 
nebulizer gas pressure was set at 55 psi. Fine tuning of nebulizer gas 
and CAD gas was done to get a consistent and stable response. Ion 
spray voltage and temperature did not have any significant impact 
on analyte response and hence were maintained at-4500 V and 500 
°C respectively. A dwell time of 500 ms was found adequate for CXB 
and IS. Also, no cross talk was observed between the MRMs of 
analyte and IS. 
 
 
Fig. 1: Product ion mass spectra of (a) celecoxib (m/z 380.0 → 315.9, scan range 70-400 Da) and (b) celecoxib-D7 (IS, m/z 387.0 → 323.0, 
scan range 100-600 Da) in the negative ionization mode 
 
The chromatographic conditions were set to obtain adequate 
retention and response with minimal interference from the 
endogenous components. This included optimization of mobile 
phase, its composition, flow rate, column type, dilution preparation 
medium and injection volume. Different combinations of 
acetonitrile/methanol and acidic buffers (ammonium formate/ 
formic acid, ammonium acetate/acetic acid) of different strengths 
(2.0-5.0 mmol) were tested as mobile phase. Further, mobile phase 
additives like formic acid and ammonium trifluoroacetate were also 
tried on Hypurity C18 (100 × 4.6 mm, 5 µm), ACE C18-300 (100 × 
4.6 mm, 5 μm), Eclipse XDB-C8 (150 × 4.6 mm, 3.5 µm), Hypurity C8 
(100 × 4.6 mm, 5 µm), ACE C8-300 (50 × 4.0 mm, 3 µm) and Kinetex 
XB C18, 100 Å (50 × 4.6 mm, 2.5 µm) columns. In addition, the effect 
of flow rate was also studied from 0.5 to 1.2 ml/min, which was 
responsible for acceptable chromatographic peak shapes and to 
separate endogenous peaks. All the columns provided acceptable 
separation of the analyte from endogenous substances within 5.0 
min but the analyte response at the QC levels was much superior on 
ACE C8-300 compared to other columns. Further, it required a run 
time of 2.5 min for the analysis of CXB and IS on this column using 
methanol-1.0 mmol ammonium acetate in 80:20 (v/v) ratio as the 
mobile phase. The analysis time was much less compared to 
previous reports [8, 10, 11], which required more than 5.0 min. 
Addition of 1.0 mmol ammonium acetate was sufficient to get 
adequate response and also good peak shape for CXB. A flow rate of 
0.5 ml/min ensured retention time of 1.44 and 1.43 min for CXB and 
IS, respectively (fig. 2). The reproducibility in the measurement of 
retention times for CXB was ≤ 0.8% (% CV) for 100 injections on the 
same column. Further, there was no effect of IS on analyte recovery, 
sensitivity or ion suppression. In the present work, PP was tried 
initially with methanol and acetonitrile; however, the samples 
obtained were not clear in either of the solvents with poor recovery 
and considerable ion suppression. LLE was also initiated with 
different solvents like diethyl ether, n-hexane, dichloromethane, 
Patel et al. 
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methyl tert-butyl ether (MTBE) and ethyl acetate, alone and in 
combination under alkaline conditions. The results obtained in 
MTBE were encouraging, but the recovery was not consistent at 
lower QC levels. Moreover, in one report the recovery of CXB 
obtained was about 45 % using MTBE as the extraction solvent 
[12]. Hence, SPE was tested with Strata-X®
  
 under acidic, neutral 
and basic conditions. Precise and quantitative recoveries (83.4-
90.2 %) with minimum matrix interference were obtained under 
acidic conditions during application of the sample on the 
cartridges. While neutral conditions (methanol-1.0 mmol 
ammonium acetate (80:20, v/v) for elution was optimal for the 
analyte and IS. 
 
Fig. 2: MRM ion-chromatograms of celecoxib (m/z 380.0 → 315.9) and celecoxib D7 (IS, m/z 387.0 → 323.0) in (a) double blank plasma 
(without analyte and IS), (b) blank plasma with IS, (c) celecoxib at LLOQ and IS (d) real subject sample at Cmax
 
Assay performance and validation 
It is indispensable to apply well-characterized and fully validated 
bioanalytical methods to obtain reliable and consistent results for 
routine analysis [18]. The developed bioanalytical method was fully 
validated for all validation parameters as explained below. 
Selectivity, carry over and interference study: The purpose of 
evaluating selectivity with 12 different human plasma sources was 
to determine the extent to which endogenous plasma components 
might interference at the retention time of CXB and the IS and thus, 
ensure the authenticity of the results for study sample analysis. Fig. 
2 demonstrates the selectivity of the method through the 
chromatograms of double blank plasma, blank plasma spiked with 
IS, CXB at LLOQ concentration respectively and in subject samples. 
Carry-over evaluation was performed in each analytical run to 
ensure that it does not impact the accuracy and precision of the 
method. The experiments showed a carryover of ≤1.07 % for CXB of 
LLOQ concentration in blank plasma sample after injection of 
highest calibration standard (ULOQ) at the retention time of analyte 
and IS. Further, there was no interference of commonly used 
medications by healthy volunteers like acetaminophen, aspirin, 
caffeine, chlorpheniramine, cetrizine, ibuprofen and pseudo-
ephedrine at the retention time of analyte and IS.  
 after administration of 400 
mg dose of celecoxib under fasting condition 
Linearity, sensitivity, accuracy and precision: The calibration curve 
were linear over the concentration range of 10.0–4000 ng/ml with 
correlation coefficient r2 ≥ 0.9987 as shown in fig. 3. A straight-line 
fit was made through the data points by least square regression 
analysis to give the mean linear equation y = (0.0012)x–(0.0001), 
where y is the peak area ratio of the analyte/IS and x the 
concentration of the analyte. The accuracy and precision (% CV) 
observed for the CSs ranged from 95.0 to 106 % and 1.6 to 5.7 %, 
respectively. The lowest concentration (LLOQ) in the standard curve 
that can be measured with acceptable accuracy and precision found 
was 10.0 ng/ml at a signal-to-noise ratio (S/N) ≥ 25, with a limit of 
detection (LOD) of 2.5 ng/ml. The intra-batch and inter-batch 
precision and accuracy results are summarized in table 1. The intra-
batch precision (% CV) ranged from 0.7 to 5.7 and the accuracy was 
within 90.2 to 104 %. For the inter-batch experiments, the precision 
varied from 1.8 to 7.2 and the accuracy was within 88.4 to 98.8 %. 
Recovery, matrix effect and post-column analyte infusion study: The 
extraction recovery and matrix effect data for the analyte and IS is 
presented in table 2. Highly consistent recovery was obtained across 
QC levels for CXB. The IS-normalized matrix factors ranged from 
0.99-1.03, which shows minimal interference of endogenous matrix 
components for CXB. Matrix effect in different plasma sources (6-
K2
Stability, dilution integrity and ruggedness study: Stability 
experiments were performed to evaluate the analyte stability in 
stocks solutions and in plasma samples under different conditions, 
simulating the same conditions which occurred during study sample 
analysis. CXB was found stable in controlled blank plasma at room 
temperature up to 25 h and for six freeze and thaw cycles. The 
analyte in extracted plasma samples was stable for 117 h under 
refrigerated conditions (2-8 °C) and for 69 h at room temperature. 
The spiked plasma samples of CXB stored at-20 °C and-70 °C for long 
term stability showed no evidence of degradation up to 126 d. The 
detailed stability results are shown in table 4. 
EDTA, 1-lipemic and 1-heamolyzed) was also evaluated at LQC 
and HQC levels. The precision values in different plasma sources 
varied from 0.5 to 2.9 % for CXB (table 3). Further, results of post-
column analyte infusion experiment showed no regions of ion 
suppression or enhancement at the retention time of analyte and IS. 
Patel et al. 




Fig. 3: Linear calibration curve for celecoxib in plasma 
 
Table 1: Intra-batch and inter-batch accuracy and precision results for celecoxib 
Analytes and  
QC level (ng/ml) 
 
Intra-day (n = 6; single batch) Inter-day (n = 18; 6 from each batch) 












LLOQ (10.00) 9.02 90.2 3.3 8.84 88.4 7.2 
LQC (30.00) 31.21 104 5.7 29.65 98.8 4.6 
MQC-2 (300.0) 278.5 92.8 1.6 274.2 91.4 2.2 
MQC-1 (1200) 1106 92.2 0.7 1097 91.4 2.5 
HQC (3000) 2801 93.4 0.9 2763 92.1 1.8 
ULOQ (4000) 3623 90.6 0.7 3554 88.9 1.8 
 LQC: low quality control; MQC: medium quality control; HQC: high quality control, LLOQ QC: lower limit of quantitation quality control; CV: 
coefficient of variation 
 









C (neat samples 







30.00 46265 41735 47734 90.2 85.1 0.97 0.94 1.03 
300.0 448323 377718 476773 84.3 84.0 0.94 0.95 0.99 
1200 1774993 1480750 1882271 83.4 85.3 0.94 0.93 1.01 
3000 4173424 3514982 4614796 84.2 84.7 0.90 0.88 1.02 
 IS: internal standard, Celecoxib-D7 
 
Table 3: Relative matrix effect in different lots of human plasma for celecoxib (n = 4) 
Plasma lots Mean calculated concentration (% CV) 
30.00 ng/ml 3000 ng/ml 
Lot-1 (K2EDTA) 31.26 (1.1) 3198 (1.8) 
Lot-2 (K2EDTA) 31.41 (0.5) 3197 (1.8) 
Lot-3 (K2EDTA) 31.04 (1.7) 3187 (2.2) 
Lot-4 (K2EDTA) 31.25 (1.8) 3189 (1.6) 
Lot-5 (K2EDTA) 31.29 (0.5) 3185 (2.5) 
Lot-6 (K2EDTA) 31.23 (0.7) 3181 (2.9) 
Lot-7 (haemolysed) 31.64 (0.6) 3185 (2.0) 
Lot-8 (lipemic) 31.04 (0.9) 3182 (1.5) 
 
Table 4: Stability results for celecoxib under different conditions (n = 6) 
Storage Condition QC level Mean stability sample (ng/ml) CV (%) Change (%) 
Bench top stability  
(25 h, 25 °C) 
LQC 28.32 1.2 -5.6 
HQC 2818 2.7 -6.1 
Freeze-thaw stability  
(6cycles,-20 °C) 
LQC 29.63 1.2 -1.2 
HQC 2892 0.9 -3.6 
Auto sampler stability  
(117 h, 2-8 °C) 
LQC 27.77 2.0 -7.4 
HQC 2698 1.2 -10.1 
Processed sample stability  
(69 h, 25 °C)  
LQC 29.56 1.4 -1.5 
HQC 2824 1.3 -5.9 
Long term stability 
(126 d,-20 °C) 
LQC 31.22 1.1 4.1 
HQC 2893 1.7 -3.6 
Long term stability 
(126 d,-70 °C) 
LQC 31.30 2.1 4.3 
HQC 2836 5.0 -5.5 
 LQC: low quality control; HQC: high quality control; CV: coefficient of variation 
Patel et al. 




Dilution integrity: The dilution reliability of the method was checked 
to confirm dilution reliability of samples having concentration above 
ULOQ. The precision (% CV) value for 10-fold dilution (20000 
ng/ml) of CXB was 1.3 % and the corresponding accuracy was 97.3 
%. The results obtained were well within the acceptance limit of 15 
% for precision (%CV) and 85 to 115 % for accuracy. Similarly, the 
precision and accuracy for method ruggedness performed on two 
different ACE C8-300 columns and with different analysts varied 
from 1.0 to 3.0 % and 95.8 to 107 %, respectively for CXB. 
Application of the method in healthy subjects 
The validated method was applied to a bioequivalence study of CXB 
under fasting and fed states in 50 and 42 healthy Indian subjects, 
respectively after oral administration of 400 mg test and reference 
formulations of CXB. The study was performed to evaluate the impact 
of food on the pharmacokinetics of CXB. The method was sensitive 
enough to monitor their plasma concentration up to 72 h. Fig. 4 shows 
the plasma concentration vs. time profile of CXB in healthy subjects 
under fasting and fed conditions. Table 5 gives a comparative 
assessment of pharmacokinetic parameters obtained for the study. 
The equivalence statistics of bioavailability for the pharmacokinetic 
parameters of the two formulations are summarized in table 6. No 
statistically significant differences were found between the two 
formulations in any parameter. Further, there was no clinically 
relevant effect of food on the pharmacokinetics of CXB. Approximately 
4641 samples including the calibration, QC and volunteer samples 
were run and analyzed successfully. The % change in the 
measurement of selected subject samples for ISR was within±20 %, 
which confirms method reproducibility. Further, there was no adverse 
event during the course of the study.  
 
Fig. 3: Mean plasma concentration-time profile of celecoxib 
after oral administration of 400 mg capsules (test and 
reference) formulation to 50 and 42 healthy Indian subjects 
under (a) fasting and (b) fed conditions, respectively
 
Table 5: Mean pharmacokinetic parameters (±SD) following of 400 mg celecoxib capsule formulation to healthy Indian subjects under 
different condition 
Parameter Fasting Fed 
Test Reference Test Reference 
Cmax (ng/ml) 1834.0±350.6 2618.0±330.6 2597.9±264.9  2525.8±259.8 
Tmax (h) 4.50±1.00 5.00±1.00 4.00±1.00  5.00±1.00 
t1/2 (h) 25.07±5.66 26.81±5.65 11.87±2.68 12.03±3.52 
AUC0-72h (h. ng/ml) 63798.3±3962.6 77354.5±4290.7 19191.1±1298.9 18613.8±1578.2  
AUC0-inf (h. ng/ml) 75374.0±4271.6 94862.1±4417.1 19563.3±1543.9 19037.8±1206.4 
Kel  (1/h) 0.123±0.028 0.123±0.026 0.0703±0.016 0.0707±0.015 
Cmax: maximum plasma concentration; Tmax:  time point of maximum plasma concentration, t1/2: half-life of drug elimination during the terminal 
phase; AUC0-t:  area under the plasma, concentration-time curve from zero hour to 72 h; AUC0-inf :  area under the plasma concentration-time curve 
from zero hour to infinity; Kel:  
 
elimination rate constant; SD: standard deviation. 
Table 6: Comparison of treatment ratios and 90% CIs of natural log (Ln)-transformed parameters for 400 mg celecoxib capsule test and 
reference formulations under fasting and fed states 
Parameter Ratio (test/ 
reference),% 
90 % confidence interval  
(Lower–upper) 
Power Intra subject variation, CV (%) 
Fast Fed Fast Fed Fast Fed Fast Fed 
Cmax (ng/ml) 105.2 102.9 97.2–113.8 98.18–107.7 0.9982 1.0000 23.86 12.51 
AUC0-72h (h. ng/ml) 104.5 103.1 99.0–110.3 99.34–107.0 1.0000 1.0000 16.11 9.99 
AUC0-inf (h. ng/ml) 103.9 102.8 98.3–109.8 98.93–106.7 1.0000 1.0000 16.61 10.21 
 CV: coefficient of variation 
 
CONCLUSION 
The present study describes a new, highly selective and rugged LC-
MS/MS method for the estimation of CXB in human plasma, 
especially to meet the requirement for subject sample analysis. The 
SPE employed in the present work using Strata X cartridges gave 
consistent and reproducible recoveries for CXB. The optimized 
linear concentration range was adequate to monitor at least five 
half-lives of CXB with good accuracy and precision. Finally, the 
reproducibility of the method was adequately proved through 
incurred sample reanalysis of subject samples for the first time. 
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